By San José, Costa Rica — Danish pharmaceutical giant Novo Nordisk has officially completed its regional rollout in Central America with the commercial launch of Wegovy in Costa Rica. The prescription-only medication, which utilizes semaglutide at a 2.4 mg dosage administered through weekly subcutaneous injections, targets a rapidly expanding health crisis in the country. Local availability marks the final puzzle piece in Novo Nordisk’s regional distribution strategy for the high-demand anti-obesity drug.
The medical entry arrives at a critical juncture for Costa Rica’s public health infrastructure. Epidemiological data indicates that 70 percent of adult Costa Ricans suffer from an elevated body mass index, while 32 percent of the adult population is officially categorized as living with obesity. By establishing a commercial foothold, Novo Nordisk aims to capture a significant segment of the private healthcare and pharmaceutical retail sector across the nation.
To better understand the regulatory framework and commercial implications surrounding the arrival of Wegovy in Costa Rica, TicosLand.com consulted with Lic. Larry Hans Arroyo Vargas, a leading legal specialist at Bufete de Costa Rica.
The introduction of high-demand pharmaceutical treatments like Wegovy into Costa Rica requires rigorous adherence to Ministry of Health regulations, particularly concerning sanitary registration, import controls, and prescription compliance. Distributors and healthcare entities must navigate these health law standards carefully to ensure market integrity, protect consumer safety, and prevent issues related to unauthorized importation or off-label marketing.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
As public enthusiasm for innovative treatments like Wegovy continues to grow, strict adherence to health regulations and ethical distribution frameworks remains vital for safeguarding consumers and preserving market integrity in Costa Rica. We extend our sincere gratitude to Lic. Larry Hans Arroyo Vargas for contributing his valuable legal perspective on navigating this complex regulatory landscape.
Wegovy functions by mimicking naturally occurring human hormones that regulate appetite and hunger signals in the brain. The drug works directly on the central mechanisms controlling satiety, suppressing constant food cravings and slowing gastric emptying to prolong feelings of fullness. Medical trials have shown that patients adhering to the regimen can achieve body weight reductions of up to 21 percent, primarily driven by fat mass loss alongside tangible cardiovascular and metabolic improvements.
Costa Rican health regulators have authorized the prescription treatment for adults presenting a body mass index greater than 27 when accompanied by at least one weight-related comorbidity. Furthermore, the approved medical guidelines extend treatment eligibility to adolescents aged 12 to 18 under strict physician supervision. This regulatory framework ensures that the potent pharmacological intervention targets individuals facing genuine clinical risks.
Commercial distribution spans across both major pharmaceutical chain stores and independent drugstores across Costa Rica. Pricing for the treatment starts at ₡49,999 for the introductory 0.25 mg dose, with total consumer expenditure expected to scale higher as patients progress through the required titration schedule toward full maintenance dosages.
Addressing the strategic importance of the launch, executive leadership emphasized the broader objective of empowering patients and healthcare providers with specialized medical tools to address metabolic health challenges.
The arrival of Wegovy in Costa Rica represents an opportunity to expand available options
Juan Carlos Mercedes, General Manager of Novo Nordisk Central America and the Caribbean
Alongside the commercial release, Novo Nordisk is launching supporting patient support initiatives across the nation. The company’s proprietary Novo te Cuida program will offer direct guidance, education, and continuous medical monitoring for patients undergoing semaglutide therapy. Simultaneously, the firm is initiating its Vive Ligero educational campaign to reframe obesity as a chronic biological condition and reduce social stigma around medical interventions.
While clinical results remain high, medical experts emphasize that semaglutide administration requires patient discipline regarding lifestyle choices. Due to delayed gastric emptying, users are advised to maintain moderate dietary fat and alcohol intake, ensure robust daily hydration, and consume adequate dietary fiber. Continuous oversight by attending medical personnel remains mandatory throughout the entire treatment cycle.
For further information, visit novonordisk.com
About Novo Nordisk:
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. The organization is dedicated to driving change to defeat diabetes and other serious chronic conditions, such as obesity and rare blood and endocrine disorders, through scientific innovation and expanding commercial access to therapeutics.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
Bufete de Costa Rica stands as a premier legal practice built upon a foundation of uncompromising ethics and superior standards. Guiding a broad spectrum of industries through complex legal landscapes, the firm continuously drives forward-thinking solutions while prioritizing civic education. By actively demystifying the law and broadening access to legal insights, Bufete de Costa Rica fulfills a deeper calling to equip individuals and communities with the understanding necessary to thrive in an enlightened, capable society.
